These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 15317469
1. Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor. Pinkerton AB, Vernier JM, Schaffhauser H, Rowe BA, Campbell UC, Rodriguez DE, Lorrain DS, Baccei CS, Daggett LP, Bristow LJ. J Med Chem; 2004 Aug 26; 47(18):4595-9. PubMed ID: 15317469 [Abstract] [Full Text] [Related]
2. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones. Pinkerton AB, Cube RV, Hutchinson JH, Rowe BA, Schaffhauser H, Zhao X, Daggett LP, Vernier JM. Bioorg Med Chem Lett; 2004 Nov 01; 14(21):5329-32. PubMed ID: 15454221 [Abstract] [Full Text] [Related]
3. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Pinkerton AB, Cube RV, Hutchinson JH, James JK, Gardner MF, Rowe BA, Schaffhauser H, Rodriguez DE, Campbell UC, Daggett LP, Vernier JM. Bioorg Med Chem Lett; 2005 Mar 15; 15(6):1565-71. PubMed ID: 15745798 [Abstract] [Full Text] [Related]
4. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Govek SP, Bonnefous C, Hutchinson JH, Kamenecka T, McQuiston J, Pracitto R, Zhao LX, Gardner MF, James JK, Daggett LP, Rowe BA, Schaffhauser H, Bristow LJ, Campbell UC, Rodriguez DE, Vernier JM. Bioorg Med Chem Lett; 2005 Sep 15; 15(18):4068-72. PubMed ID: 16005222 [Abstract] [Full Text] [Related]
5. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators. Pinkerton AB, Cube RV, Hutchinson JH, James JK, Gardner MF, Schaffhauser H, Rowe BA, Daggett LP, Vernier JM. Bioorg Med Chem Lett; 2004 Dec 06; 14(23):5867-72. PubMed ID: 15501058 [Abstract] [Full Text] [Related]
6. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE. Biochem Soc Trans; 2004 Nov 06; 32(Pt 5):881-7. PubMed ID: 15494040 [Abstract] [Full Text] [Related]
7. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD. J Med Chem; 2003 Jul 17; 46(15):3189-92. PubMed ID: 12852748 [Abstract] [Full Text] [Related]
8. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR. J Med Chem; 2004 Nov 18; 47(24):5825-8. PubMed ID: 15537338 [Abstract] [Full Text] [Related]
9. Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bonnefous C, Vernier JM, Hutchinson JH, Gardner MF, Cramer M, James JK, Rowe BA, Daggett LP, Schaffhauser H, Kamenecka TM. Bioorg Med Chem Lett; 2005 Oct 01; 15(19):4354-8. PubMed ID: 16046122 [Abstract] [Full Text] [Related]
10. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. Lesage A, Steckler T. Eur J Pharmacol; 2010 Aug 10; 639(1-3):2-16. PubMed ID: 20371230 [Abstract] [Full Text] [Related]
11. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ. Neuropsychopharmacology; 2003 Sep 10; 28(9):1622-32. PubMed ID: 12825094 [Abstract] [Full Text] [Related]
12. [Targeting metabotropic glutamate receptors to develop novel antipsychotics]. Chaki S, Yoshida S, Okuyama S. Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov 10; 30(5-6):207-13. PubMed ID: 21226317 [Abstract] [Full Text] [Related]
13. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, Kimura T, Tanak T, Ito S, Kawamoto H, Ohta H. J Pharmacol Exp Ther; 2008 Aug 10; 326(2):577-86. PubMed ID: 18487514 [Abstract] [Full Text] [Related]
14. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL. J Pharmacol Exp Ther; 2008 Dec 10; 327(3):827-39. PubMed ID: 18753411 [Abstract] [Full Text] [Related]
15. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Fraley ME. Expert Opin Ther Pat; 2009 Sep 10; 19(9):1259-75. PubMed ID: 19552508 [Abstract] [Full Text] [Related]
16. 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Brnardic EJ, Fraley ME, Garbaccio RM, Layton ME, Sanders JM, Culberson C, Jacobson MA, Magliaro BC, Hutson PH, O'Brien JA, Huszar SL, Uslaner JM, Fillgrove KL, Tang C, Kuo Y, Sur SM, Hartman GD. Bioorg Med Chem Lett; 2010 May 15; 20(10):3129-33. PubMed ID: 20409708 [Abstract] [Full Text] [Related]
17. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H. J Pharmacol Exp Ther; 2007 Jun 15; 321(3):1144-53. PubMed ID: 17360958 [Abstract] [Full Text] [Related]
18. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Barda DA, Wang ZQ, Britton TC, Henry SS, Jagdmann GE, Coleman DS, Johnson MP, Andis SL, Schoepp DD. Bioorg Med Chem Lett; 2004 Jun 21; 14(12):3099-102. PubMed ID: 15149652 [Abstract] [Full Text] [Related]